CClinicalTrials.gg
Status unknownNCT03051308Updated Feb 13, 2017

University of Wisconsin Solution Versus New Parathyroid Transport Solution for Parathyroid Allotransplantation

An interventional study of NPT and UW Solution in Parathyroid Allotransplantation, sponsored by SB Istanbul Education and Research Hospital. Status unknown at 1 site in Turkey. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-02-13.

Sponsored by SB Istanbul Education and Research Hospital · Not applicable, Interventional, and Basic science

The sponsor has not verified this record recently (last verified Feb 2017), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
7
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Compare the functionality of new parathyroid transport solution (NPTS) with University of Wisconsin Solution (UW) on parathyroid glands. Also assess its effects on cell viability, parathormone (PTH) secretion, calcium-sensing receptor (CaSR) and vitamin D receptor (VDR) levels during cold ischemia.

Read the detailed description

Parathormone (PTH) and vitamin D are two critical hormonal regulators of calcium homeostasis. There is an important relationship between the PTH release and vitamin D receptor for controlling hormonal systems. Also calcium-sensing receptor plays a crucial role in regulating parathormone secretion which means controlling the calcium-dependent systemic ion homeostasis.

Cold ischemia protects organs and tissues by slowing their metabolism. The cold ischemia of the transplant tissue is a very important process. The University of Wisconsin (UW) solution substantially improves graft preservation and consequently increases patient survival. The researchers newly developed NPTS for transportation of parathyroid glands.

For the comparision the researchers measured the parathyroid cell viability and the calcium sensing and vitamin D receptor density of the parathyroid cells at the 0, 6, 12 and 24 hours of cold ischemia.

02

Conditions studied

  • Parathyroid Allotransplantation

Keywords

  • Parathyroid cell viability
  • Ischemia
  • Parathyroid allotransplantation
  • Vitamin D Receptor
  • Calcium Sensing Receptor
03

In context

Lead sponsor

SB Istanbul Education and Research Hospital is the lead sponsor of 19 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients who have parathyroid hyperplasia due to chronic renal failure.

Exclusion criteria

Exclusion Criteria:

  • Patients who refused to join the study
  • Patients younger than 18 years and older than 80 years.
  • Patients who have hepatitis B,
  • Patients who have hepatitis C,
  • Patients who have human immunodeficiency virus (HIV).
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
7 participants (estimated)

Study arms

  • Experimental
    First Application in Hour 0

    Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10\^7 cells) at 'First Application in Hour 0' non-cold ischemia tissue group

    Combination Product: NPT and UW Solution

  • Experimental
    First Application in Hour 6

    Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10\^7 cells) at 'First Application in Hour 6' cold ischemic tissue group

    Combination Product: NPT and UW Solution

  • Experimental
    First Application in Hour 12

    Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10\^7 cells) at 'First Application in Hour 12' cold ischemic tissue group

    Combination Product: NPT and UW Solution

  • Experimental
    First Application in Hour 18

    Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10\^7 cells) at 'First Application in Hour 18' cold ischemic tissue group

    Combination Product: NPT and UW Solution

  • Experimental
    First Application in Hour 24

    Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10\^7 cells) at 'First Application in Hour' 24 cold ischemic tissue group

    Combination Product: NPT and UW Solution

Interventions

  • Combination productNPT and UW Solution

    Tissue preservation solutions for transplantation

06

What researchers measure

Primary outcomes

  1. Cell viability of Parathyroid cells after isolation process

    After removal of hyperplastic parathyroid glands, each gland will keep in ice cold NPTS and UW solution for transportation to laboratory. Then the investigators will measure the viability of Parathyroid cells after isolation process.

    Time frame: 0 hour

  2. Cell viability of Parathyroid cells after 6 hour of cold ischemia

    After removal of hyperplastic parathyroid glands, each gland will keep in ice cold NPTS and UW solution for transportation to laboratory. After 6 hours the investigators will measure the viability of Parathyroid cells after isolation process.

    Time frame: 6 hour

  3. Cell viability of Parathyroid cells after 12 hour of cold ischemia

    After removal of hyperplastic parathyroid glands, each gland will keep in ice cold NPTS and UW solution for transportation to laboratory. After 12 hours the investigators will measure the viability of Parathyroid cells after isolation process.

    Time frame: 12 hour

  4. Cell viability of Parathyroid cells after 18 hour of cold ischemia

    After removal of hyperplastic parathyroid glands, each gland will keep in ice cold NPTS and UW solution for transportation to laboratory. After 18 hours the investigators will measure the viability of Parathyroid cells after isolation process.

    Time frame: 18 hour

  5. Cell viability of Parathyroid cells after 24 hour of cold ischemia

    After removal of hyperplastic parathyroid glands, each gland will keep in ice cold NPTS and UW solution for transportation to laboratory. After 24 hours the investigators will measure the viability of Parathyroid cells after isolation process.

    Time frame: 24 hour

Secondary outcomes

  1. Parathormone Release of Parathyroid Cells

    The investigators will measure the parathormone level from cultured parathyroid cells

    Time frame: 1 day

07

Study locations

1 of 1 sites recruiting
  • Bezmialem Vakif University Hospital
    Istanbul, 34093, Turkey
    Recruiting
08

References and documents

Publications

  • Belzer FO, Southard JH. Principles of solid-organ preservation by cold storage. Transplantation. 1988 Apr;45(4):673-6. doi: 10.1097/00007890-198804000-00001. No abstract available. PubMed 3282347 ↗
  • Southard JH, van Gulik TM, Ametani MS, Vreugdenhil PK, Lindell SL, Pienaar BL, Belzer FO. Important components of the UW solution. Transplantation. 1990 Feb;49(2):251-7. doi: 10.1097/00007890-199002000-00004. PubMed 1689516 ↗
  • Guibert EE, Petrenko AY, Balaban CL, Somov AY, Rodriguez JV, Fuller BJ. Organ Preservation: Current Concepts and New Strategies for the Next Decade. Transfus Med Hemother. 2011;38(2):125-142. doi: 10.1159/000327033. Epub 2011 Mar 21. PubMed 21566713 ↗
  • Voigt MR, DeLario GT. Perspectives on abdominal organ preservation solutions: a comparative literature review. Prog Transplant. 2013 Dec;23(4):383-91. doi: 10.7182/pit2013100. PubMed 24311404 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03051308
Lead sponsor
SB Istanbul Education and Research Hospital
Collaborators
Bezmialem Vakif University
Responsible party
Erhan Aysan (Principal Investigator, SB Istanbul Education and Research Hospital) — Principal investigator
First posted
Feb 13, 2017
Start date
Mar 1, 2017 (estimated)
Primary completion
Jun 1, 2017 (estimated)
Completion
Jul 1, 2017 (estimated)
Last update
Feb 13, 2017

Study contacts

Erhan Aysan, Prof. M.D.
Contact
erhanaysan@hotmail.com
+902124531700 ext. 2465
Beyza Goncu, Msc
Contact
bsgoncu@gmail.com
+902124531700 ext. 1465
Erhan Aysan, Prof. M.D.
study director · Bezmialem Vakif University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion